Why This Case Is So Popular

With 158 completed practice sessions from 112 unique trainees, the Menopause and HRT case is the fifth most practised scenario on MedTutor. It also has one of the higher repeat rates: 1.41 sessions per trainee.

Three reasons this case keeps pulling trainees in:

It tests shared decision-making under pressure. The patient typically presents with menopausal symptoms and wants to discuss HRT. Our data shows that shared decision-making is weak in 24.1% of all practice consultations, and this case exposes that weakness more than most.

The clinical content is dense. NICE NG23 covers vasomotor symptoms, urogenital symptoms, mood changes, cardiovascular risk, osteoporosis, breast cancer risk, different HRT formulations, non-hormonal alternatives, and monitoring. You cannot cover everything in 12 minutes.

The emotional dimension is significant. Menopause affects women physically, emotionally, and psychologically. If you treat this as a purely clinical discussion about oestrogen and progesterone, you miss the person in front of you.

Women's Health as a whole is the second most practised clinical area on MedTutor (726 sessions across 189 trainees).

NICE Guideline Essentials for the SCA

You do not need to memorise every detail of NICE NG23. But you need to know:

Diagnosis. Menopause is a clinical diagnosis in women over 45 with typical symptoms. No blood tests are needed unless the clinical picture is unclear.

First-line HRT. For women with a uterus: oestrogen (transdermal preferred) plus micronised progesterone. For women without a uterus: oestrogen only. Transdermal oestrogen is preferred because it does not increase VTE risk.

Key contraindications. Undiagnosed vaginal bleeding, current or recent breast cancer, active liver disease, untreated endometrial hyperplasia.

Vaginal symptoms. Vaginal oestrogen can be offered for urogenital symptoms alone, with or without systemic HRT. It can be used long-term and does not need progesterone cover.

Non-hormonal alternatives. CBT has evidence for vasomotor symptoms and mood changes. SSRIs/SNRIs can help hot flushes (off-label). Lifestyle measures have some evidence.

Duration and monitoring. Review HRT annually. There is no arbitrary time limit.

The Breast Cancer Risk Conversation

This is the part of the consultation that most trainees find hardest.

Use absolute risk, not relative risk. For women aged 50 to 59 taking combined HRT for 5 years, there are approximately 4 additional cases of breast cancer per 1,000 women. For oestrogen-only HRT, the additional risk is smaller, approximately 0 to 1 extra cases per 1,000 over 5 years.

How to communicate this clearly:

"I want to talk about the breast cancer question because I know it's something a lot of women worry about. The research shows that combined HRT does slightly increase the risk of breast cancer. To put it in perspective: out of 1,000 women your age who take combined HRT for 5 years, there would be about 4 extra cases of breast cancer compared to women who do not take it. That is a small increase, and it is similar to the increased risk from drinking two glasses of wine a day or being significantly overweight."

What NOT to do:

Do not say "There is a slightly increased risk" without quantifying it. Do not dismiss the concern with "It is very rare." Do not avoid the topic hoping the patient will not ask.

This section is where Relating to Others and Clinical Management overlap.

Shared Decision-Making in Practice

Present the options clearly. "Based on what you've told me, there are a few things we could consider. HRT would be the most effective option for your hot flushes and night sweats. There are also non-hormonal options like CBT. And there are lifestyle changes that can make a difference too. I'd like to hear what feels right for you."

Explore the patient's preference. "You mentioned you've been reading about HRT online. What were your thoughts about trying it?"

Respect the decision. If the patient decides she does not want HRT, support that decision. Offer alternatives and a clear follow-up plan.

If the patient decides to start HRT, confirm the formulation, explain how to use it, discuss what to expect, and arrange follow-up.

Common Mistakes from Practice Data

Based on the AI feedback patterns across 158 completed sessions:

Launching into HRT options before exploring symptoms and concerns. The most common mistake. The ICE exploration weakness is particularly visible in this case.

Not screening for contraindications. The SCA expects you to demonstrate safe prescribing.

Giving vague risk information. "There's a small risk of breast cancer" is not sufficient. Examiners expect absolute numbers.

Forgetting non-hormonal alternatives. Some trainees present HRT as the only option.

Rushing the management plan. Follow-up planning is incomplete in 49.9% of sessions.

Not acknowledging the broader impact. Menopause affects sleep, mood, relationships, work, and self-image. Even a brief acknowledgement shows the examiner you are consulting holistically.

How to Score Well: Domain by Domain

Data Gathering and Diagnosis

Take a focused menopausal symptom history: vasomotor, urogenital, mood, cognitive, and musculoskeletal. Screen for contraindications. Ask about menstrual history. Explore what the patient has tried so far.

Score well by: Demonstrating a structured approach to symptom assessment and screening for contraindications unprompted.

Clinical Management and Medical Complexity

Know the first-line HRT recommendation. Discuss risks and benefits using absolute numbers. Offer genuine alternatives. Provide a clear follow-up plan.

Score well by: Recommending evidence-based treatment aligned to NICE NG23 and communicating risk clearly.

Relating to Others

Explore ICE early. Acknowledge the broader impact of menopause. Involve the patient in the decision. Close with warmth.

Score well by: Making the patient feel heard and giving her agency in the decision.